Hikma Pharmaceuticals

Activities: Manufacturing

Trending Articles

  1. NICE approves KEYTRUDA as first perioperative immunotherapy for locally advanced head and neck cancer MSD's KEYTRUDA (pembrolizumab) has received NICE approval as a neoadjuvant and adjuvant therapy for resectable LA HNSCC—the first immunotherapy recommended in this...
  2. Destination Russia for new NYK Logistics warehouse Logistics specialist NYK is expanding its market presence with the launch of new warehousing operation in Moscow, Russia.
  3. Pfizer agrees sale of consumer healthcare business to J&J Pfizer Inc has reached an agreement to sell its consumer healthcare business to Johnson & Johnson (J&J) for US$16.6bn (euro13.2bn) in cash.
  4. Pfizer's HYMPAVZI receives positive CHMP opinion for haemophilia A and B patients with inhibitors The EMA's Committee for Medicinal Products for Human Use has recommended expanding the approved indication for Pfizer's HYMPAVZI to include adolescents and adults with...
  5. AstraZeneca's tozorakimab meets primary endpoint in both Phase III COPD trials AstraZeneca has reported positive results from the OBERON and TITANIA Phase III trials, with tozorakimab significantly reducing moderate-to-severe COPD exacerbations compared...

Upcoming event

Making Pharmaceuticals

21–22 April 2026 | Exhibition | Coventry, UK See all

Related Content

Regulatory

Status update on ANDA for generic Advair Diskus (VR315 [US])

Vectura Group, an industry leading inhalation CDMO, confirms the announcement made by its partner Hikma Pharmaceuticals
Manufacturing

Hikma capitalises on Insys Therapeutics bankruptcy

The acquisition includes unit-dose nasal and sublingual spray manufacturing equipment as well as two pipeline products
Manufacturing

Hikma establishes distribution partnership with Melinta

The agreement covers distribution of an antibiotic effective against MRSA across the Middle East and North African region
Distribution

Hikma announces exclusive agreement with Sciecure Pharma for niche injectable antiviral medicine

Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world
Regulatory

Hikma launches Dalfampridine Extended-release tablets

Hikma Pharmaceuticals, formerly known as West-Ward Pharmaceuticals, has launched Dalfampridine Extended-release tablets, 10 mg, the generic therapeutic equivalent to Ampyra
Pharmaceutical

Hikma launches Clobazam oral suspension and Clobazam tablets

Hikma Pharmaceuticals has launched Clobazam oral suspension, 2.5 mg/mL, and Clobazam tablets, 10 and 20 mg, the generic equivalent to Onfi
Recruitment

Hikma Pharmaceuticals appoints VP of Sales and Marketing
Subscribe now